ScreenerHero
AMLXAmylyx Pharmaceuticals Inc. Common Stock
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · amylyx.com
40.78USD+5.65%Mkt Cap: 4.30B $P/E: —

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provid…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.46BUSDP/E 37.1

Key Statistics

Company
Market Cap4.30B $
Enterprise Value4.17B $
Revenue (TTM)—
Gross Profit0 $
Net Income (TTM)-144.74M $
Revenue/Share—
Last Price40.78 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees136
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-34.35
PEG—
EV/EBITDA-25.80
EV/Revenue—
P/S—
P/B18.46
EPS (TTM)-1.45
EPS (Forward)-1.15
52W Range
7.630100% of range39.06
52W High39.06 USD
52W Low7.630 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-47.41%
ROA-43.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-123.34M $
CapEx (TTM)138.00K $
FCF Margin—
FCF Yield-1.80%
Net Debt-245.50M $
Net Debt/EBITDA1.52
Balance Sheet
Debt/Equity0.02
Current Ratio12.12
Quick Ratio11.88
Book Value/Sh2.148 USD
Cash/Share2.251 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)42.18 USD
Upside (mean)+3.4%
Target Range20.00 USD – 55.00 USD
$20.00+3.4% to mean$55.00
# Analysts11
Ownership
Shares Out.111.42M
Float82.57M
Insiders7.87%
Institutions105.60%
Short Interest
Short Ratio7.7d
Short % Float15.56%
Short % Out.12.03%
Shares Short13.40M
Short (prev mo.)14.39M
Technical
SMA 5019.76 (+106.3%)
SMA 20015.61 (+161.2%)
Beta-0.20
S&P 52W Chg18.16%
Avg Vol (30d)1.94M
Avg Vol (10d)5.08M
Technical Indicators
RSI (14)85.2
MACD2.5272
MACD Signal1.6212
MACD Hist.+0.9059
BB Upper30.65 USD
BB Middle21.91 USD
BB Lower13.17 USD
BB Width79.75%
ATR (14)2.462 USD
Vol Ratio (20d)4.22x